Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Femasys Inc. - Common Stock (NQ:FEMY)

0.4551 +0.0060 (+1.34%)
Streaming Delayed Price Updated: 11:13 AM EDT, May 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 208,259
Open 0.4554
Bid (Size) 0.4525 (200)
Ask (Size) 0.4577 (300)
Prev. Close 0.4491
Today's Range 0.4400 - 0.4599
52wk Range 0.3067 - 1.161
Shares Outstanding 11,813,610
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026
Expanding commercialization of first-line fertility treatment in the OB/GYN office to increase patient access 
From Femasys Inc.
Via GlobeNewswire

Performance

YTD
-28.5%
-28.5%
1 Month
+15.9%
+15.9%
3 Month
-6.2%
-6.2%
6 Month
-41.7%
-41.7%
1 Year
-60.1%
-60.1%

More News

Read More
News headline image
Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Traders are paying attention to the gapping stocks in Monday's session. ↗
Via Chartmill
News headline image
Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care
From Femasys Inc.
Via GlobeNewswire
News headline image
Traders are paying attention to the gapping stocks in Monday's session. ↗
Via Chartmill
News headline image
Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device
From Femasys Inc.
Via GlobeNewswire
News headline image
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
PMCB Stock Jumps 25% After Company Sells Stake In Femasys ↗
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Femasys Announces Third Quarter Financial Results for 2025
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe
From Femasys Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
Femasys Stock Sparks Retail Frenzy After FDA Clears Final Phase Of FemBloc Trial And $58M Financing ↗
Via Stocktwits
News headline image
Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million
From Femasys Inc.
Via GlobeNewswire
News headline image
Get insights into the top gainers and losers of Friday's pre-market session. ↗
Via Chartmill

Frequently Asked Questions

Is Femasys Inc. - Common Stock publicly traded?
Yes, Femasys Inc. - Common Stock is publicly traded.
What exchange does Femasys Inc. - Common Stock trade on?
Femasys Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Femasys Inc. - Common Stock?
The ticker symbol for Femasys Inc. - Common Stock is FEMY on the Nasdaq Stock Market
What is the current price of Femasys Inc. - Common Stock?
The current price of Femasys Inc. - Common Stock is 0.4551
When was Femasys Inc. - Common Stock last traded?
The last trade of Femasys Inc. - Common Stock was at 05/08/26 11:13 AM ET
What is the market capitalization of Femasys Inc. - Common Stock?
The market capitalization of Femasys Inc. - Common Stock is 5.38M
How many shares of Femasys Inc. - Common Stock are outstanding?
Femasys Inc. - Common Stock has 5M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.